Thomas Lenzmeier, MD
Family Medicine · Glendale, AZNPI 1932120441
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,471 of the $3,556 with a category attached, or 69.5%. 18 manufacturers reported payments, led by Novo Nordisk AS at 33.1% of the total. Reporting peaked in 2019 at $1,546 and has fallen 62.7% since, to $576 in 2025.
Across 110 payments — averaging $32.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$1K
- Novo Nordisk$1K
- AstraZeneca$279
- Lilly USA, LLC$269
- Pfizer$143
- Edwards Lifesciences$132
- plus $517 from 12 others
Across 1,221 payments — averaging $3661.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1.6M
- Modernatx, Inc.$964K
- Merck$735K
- Bavarian Nordic A/s$280K
- AstraZeneca$236K
- Novo Nordisk AS$232K
- plus $403K from 7 others
What the payments were for
- Travel & lodging$71720%
- Food & beverage$2,47170%
- Education$36710%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 6 | $1,176 |
| Novo Nordisk | 35 | $1,039 |
| AstraZeneca | 19 | $279 |
| Lilly USA, LLC | 12 | $269 |
| Pfizer | 6 | $143 |
| Edwards Lifesciences | 3 | $132 |
| Merck | 6 | $111 |
| GSK | 6 | $106 |
| Sanofi Pasteur Inc. | 3 | $66 |
| Boston Scientific | 3 | $56 |
| Abbott | 2 | $37 |
| Amgen | 2 | $34 |
| Seqirus USA Inc | 2 | $33 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Exact Sciences | 1 | $14 |
| Hologic Sales And Service, LLC | 1 | $14 |
| Phadia US Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,556 in reported general payments places this provider in the 85th percentile of 2,099 family medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 86 | $111,425 |
| JardianceEmpagliflozin | 72 | $72,384 |
| OzempicSemaglutide | 54 | $66,448 |
| TrulicityDulaglutide | 43 | $63,288 |
| FarxigaDapagliflozin Propanediol | 31 | $28,800 |
| ProliaDenosumab | 16 | $27,726 |
| EliquisApixaban | 16 | $18,543 |
| Tresiba Flextouch U-200Insulin Degludec | 23 | $17,589 |
| Spiriva HandihalerTiotropium Bromide | 24 | $14,258 |
| SymbicortBudesonide/Formoterol Fumarate | 26 | $8,508 |
| Atorvastatin Calcium | 633 | $6,535 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $6,381 |
| Rosuvastatin Calcium | 512 | $6,206 |
| Levothyroxine Sodium | 338 | $3,942 |
| Lisinopril | 398 | $3,476 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $269 | $174,714129 claims |
| Novo NordiskOzempic | $1,039 | $66,44854 claims |
| AstraZenecaFarxiga, Symbicort | $279 | $37,30857 claims |
| AmgenProlia | $34 | $27,72616 claims |
| PfizerEliquis | $143 | $18,54316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,099 family medicine providers in Arizona.
Other family medicine in Glendale
- Rachel LanglandGlendale$83K
- Kecia SmetteGlendale$41K
- Donald MiddletonGlendale$24K
- Michaela SkellyGlendale$21K
- Clark WysongGlendale$14K
- Douglas CunninghamPhoenix$1.8M
- Mitchell EdelsteinPhoenix$741K
- Lorena Jauregui-CovarrubiasYuma$491K
- Sam FereidouniScottsdale$486K
- Jessica BlancoChandler$447K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.